Dimethyl fumarate (Biogen Idec, Inc, Cambridge, MA, USA) is an FDA approved oral treatment for relapsing MS. One phase II and 2 phase III randomized, placebo-controlled and double-blinded clinical trials established that dimethyl fumarate significantly reduces relapse rates and improves disability along with neuroradiologic outcomes relative to placebo.